<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986401</url>
  </required_header>
  <id_info>
    <org_study_id>MA-SXR-09-002</org_study_id>
    <nct_id>NCT00986401</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects</brief_title>
  <official_title>Safety and Tolerability of Trospium Chloride Metformin Hydrochloride in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of trospium chloride
      (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®</measure>
    <time_frame>34 Days</time_frame>
    <description>Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®</measure>
    <time_frame>34 Days</time_frame>
    <description>Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Glucophage® then Sanctura XR® (AB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sanctura XR® then Glucophage® (BA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trospium Chloride (Sanctura XR®)</intervention_name>
    <description>extended release, 60 mg, oral daily</description>
    <arm_group_label>Sanctura XR® then Glucophage® (BA)</arm_group_label>
    <other_name>Sanctura XR® 60 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochloride (Glucophage®)</intervention_name>
    <description>immediate release, 500mg</description>
    <arm_group_label>Glucophage® then Sanctura XR® (AB)</arm_group_label>
    <other_name>Glucophage®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight within +/-30% of ideal body weight for height and frame size

          -  Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine
             patches, etc., for 1 months prior to the screening visit).

          -  Willing to abstain from caffeine-containing food and beverages for 24-hours prior to
             dosing, alcohol-containing food and beverage for 48 hours prior to dosing, and Seville
             oranges (eg orange marmalade), grapefruit, or grapefruit juice for 7 days prior to the
             dosing and abstain from all throughout the study.

          -  Willing to abstain from taking medications (with the exception of hormonal
             contraceptives) and nonprescription medication including vitamins, food supplements,
             and herbal preparations for 7 days prior to Day-1 of the first treatment period and
             throughout the study.

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Known allergy or sensitivity to the study medication(s) (Trospium, Metformin)or its
             components

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study.

          -  History of myasthenia gravis or closed-angle glaucoma.

          -  Considering or scheduled to undergo any surgical procedure during the study.

          -  History of alcohol or substance abuse within 1 year prior to Day-1 of the first
             treatment period.

          -  History of serious mental or physical illness.

          -  Donated in excess of 500 mL of blood in the 30 days prior to the screening visit.

          -  Required treatment with any medications, either prescription or nonprescription
             (including vitamins, antacids, acid-reducers, food supplements, and herbal
             preparations, excluding hormonal contraceptives), within 7 days prior to Day-1 of the
             first treatment period during the study.

          -  Had an acute illness within 5 days prior to Day-1 of the treatment period.

          -  Had a history of hepatitis B or C, a positive test for hepatitis B surface antigen,
             hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or
             demonstration of HIV antibodies.

          -  Planned radiologic study requiring intravenous contrast administration of iodinated
             contrast material during the study period Serum Creatinine greater than 1.4 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <results_first_submitted>November 16, 2011</results_first_submitted>
  <results_first_submitted_qc>November 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2011</results_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Trospium chloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glucophage® Then Sanctura XR® (AB)</title>
          <description>Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.</description>
        </group>
        <group group_id="P2">
          <title>Sanctura XR® Then Glucophage® (BA)</title>
          <description>Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glucophage® Then Sanctura XR® (AB)</title>
          <description>Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.</description>
        </group>
        <group group_id="B2">
          <title>Sanctura XR® Then Glucophage® (BA)</title>
          <description>Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.0" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="B2" value="30.2" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="B3" value="31.0" lower_limit="18" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®</title>
        <description>Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.</description>
        <time_frame>34 Days</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized). One patient was not included in the analysis due to early discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glucophage®</title>
            <description>Glucophage®</description>
          </group>
          <group group_id="O2">
            <title>Glucophage® + Sanctura XR®</title>
            <description>Glucophage® + Sanctura XR®</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®</title>
          <description>Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized). One patient was not included in the analysis due to early discontinuation.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="739" spread="263"/>
                    <measurement group_id="O2" value="753" spread="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®</title>
        <description>Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
        <time_frame>34 Days</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study (randomized). One patient was not included in the analysis due to early discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sanctura XR®</title>
            <description>Sanctura XR®</description>
          </group>
          <group group_id="O2">
            <title>Sanctura XR® + Glucophage®</title>
            <description>Sanctura XR® + Glucophage®</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®</title>
          <description>Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.</description>
          <population>Intent-to-treat, which includes all patients who started the study (randomized). One patient was not included in the analysis due to early discontinuation.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="1.44"/>
                    <measurement group_id="O2" value="1.17" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population was used to calculate the number of participants at risk for SAEs and AEs and is the total number of patients that were randomized AND treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glucophage®</title>
          <description>Glucophage®</description>
        </group>
        <group group_id="E2">
          <title>Sanctura XR®</title>
          <description>Sanctura XR®</description>
        </group>
        <group group_id="E3">
          <title>Sanctura XR® in Combination With Glucophage®</title>
          <description>Sanctura XR® in combination with Glucophage®</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Medical Affairs</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

